Boston Scientific (BSX) Tops Q4 EPS by 2c, Beats on Revenue; Offers FY26 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Boston Scientific (BSX) PT Lowered to $105 at Piper Sandler, 'Buy The Dip'
February 4, 2026 9:46 AM EST(Updated - February 4, 2026 9:52 AM EST)
Piper Sandler analyst Matt O\'Brien lowered the price target on Boston Scientific (NYSE: BSX) to $105.00 (from $120.00) while maintaining a Overweight rating.
"Q4 Beat But Key Drivers Deceleration to Weight on Stock; Buy The Dip"... More